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Interleukin-13 Receptor alpha 2 (IL-13Ra2) is a tumor
antigen and a potent target for cancer therapy. Pre-
viously, we have reported that histone deacetylase
(HDAC) inhibitors upregulated the IL-13Ra2 expression
and enhanced anti-cancer effects of IL-13-PE, an immu-
notoxin composed of interleukin-13 and truncated Pseu-
domonas exotoxin, in a mouse model of human
pancreatic cancer. Herein, we have investigated whether
HDAC inhibitors can enhance the effect of IL-13-PE in
immunocompetent mouse tumor models by upregulat-
ing IL-13Ra2. We analyzed mRNA and protein levels of
mouse IL-13Ra2 in four mouse tumor cell lines,
MCA304 sarcoma, 4T1 breast cancer, GL261 glioma
and D5 melanoma. By RT-PCR analysis, mRNA levels
for IL-13Ra2 were high in MCA304, moderate in 4T1,
low in GL261 and below the detection limit in D5
mouse tumor cell lines. These cell lines were treated
with three types of HDAC inhibitors, trichostatin A,
sodium butyrate and suberoylanilide hydroxamic acid
(SAHA) to evaluate their effects on IL-13Ra2 expression
in vitro. All HDAC inhibitors dramatically increased IL-
13Ra2 mRNA expression in MCA304, 4T1, and GL261
cell lines. The D5 tumor cell line showed only a slight
increase in mRNA levels of IL-13Ra2. Western blot ana-
lysis for IL-13Ra2 demonstrated increased levels of IL-
13Ra2 protein in all of the HDAC inhibitor treated
tumor cells. We also observed that all three HDAC inhi-
bitors selectively enhanced cytotoxicity of IL-13-PE in
MCA304 and 4T1 cell lines. TSA treatment resulted in
maximum improvement of IL-13-PE induced cytotoxi-
city in MCA304, NaB in GL261, and SAHA in 4T1 cell
lines. We next developed a subcutaneous tumor model
of mouse sarcoma by implanting MCA304 tumor cells
in C57BL/6 mice. Mice were treated with SAHA (an
FDA licensed drug) i.p. at 25mg/kg/day dose from day 4
through 9 prior to IL-13-PE immunotoxin treatment.
IL-13-PE was administered at a 250mg/kg dose intratu-
morally from day 5 through 9. Mice treated with vehicle
control and SAHA showed tumor growth to ~1500
mm3 in ~22 days and were sacrificed because of ethical
reasons. Treatment with IL-13-PE alone showed a sig-
nificant reduction in tumor growth and mice survived
longer. Tumor size reached ~750 mm3 in 35 days. How-
ever, when IL-13-PE was administered to SAHA pre-
treated mice, tumor size showed further reduction and
reached only ~400 mm3 on day 35. Additional studies
are ongoing to determine the mechanism of synergistic
antitumor effects of HDAC inhibitors and IL-13-PE.
These results suggest that HDAC inhibitors may upre-
gulate tumor antigens in vivo and thus may be consid-
ered in combination with cancer vaccines and
immunotherapy products for cancer therapy.
Authors’ details
1DCGT, OCTGT, CBER, US FDA, Bethesda, MD, USA. 2NTT Medical Center
Tokyo, Tokyo, Japan.
1DCGT, OCTGT, CBER, US FDA, Bethesda, MD, USA
Full list of author information is available at the end of the article
Fujisawa et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P73
http://www.immunotherapyofcancer.org/content/1/S1/P73
© 2013 Fujisawa et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P73
Cite this article as: Fujisawa et al.: Histone deacetylase inhibitiors
enhance sensitivity of murine sarcoma tumors to
IL-13-PE immunotoxin-based cancer therapy by upregulating IL-13Ra2
expression in vitro and in vivo. Journal for ImmunoTherapy of Cancer 2013
1(Suppl 1):P73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fujisawa et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P73
http://www.immunotherapyofcancer.org/content/1/S1/P73
Page 2 of 2
